Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA (AZN)
Mes dernières consult.
Most popular
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
07/17/2017 07/18/2017 07/19/2017 07/20/2017 07/21/2017 Date
5040(c) 5069(c) 5070(c) 5123(c) 5150 Last
1 735 352 1 763 249 1 181 548 1 060 849 798 190 Volume
+0.83% +0.58% +0.02% +1.05% +0.53% Change
More quotes
Financials ($)
Sales 2017 21 464 M
EBIT 2017 5 969 M
Net income 2017 2 628 M
Debt 2017 12 461 M
Yield 2017 4,11%
Sales 2018 22 254 M
EBIT 2018 6 272 M
Net income 2018 3 248 M
Debt 2018 13 496 M
Yield 2018 4,15%
P/E ratio 2017 30,92
P/E ratio 2018 24,72
EV / Sales2017 4,51x
EV / Sales2018 4,40x
Capitalization 84 409 M
More Financials
Company
AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products.The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases.Its... 
Sector
Pharmaceuticals
Calendar
07/27Earnings Release
More about the company
Surperformance© ratings of AstraZeneca
Trading Rating : Investor Rating :
More Ratings
Latest news on ASTRAZENECA
03:05p GlaxoSmithKline's new CEO prepares to trim drug pipeline
07/20 ASTRAZENECA : Patent Issued for Method and Device for Detection of Bioavailable ..
07/20 ASTRAZENECA : New Medicinal Chemistry Study Findings Recently Were Reported by R..
07/20 ASTRAZENECA : Kyntheum approved in the EU for the treatment of adults with moder..
07/16 ASTRAZENECA : Soriot not moving to Teva - Bloomberg
07/16 ASTRAZENECA : Maybe AstraZeneca Can Help?
07/14DJASTRAZENECA : CEO? We Still Don't Know If He's Staying or Going
07/14 ASTRAZENECA : offers no comment after report saying CEO staying
07/14 FTSE falters, narrowing weekly gain; Carillion sees small bounce
07/14 ASTRAZENECA : gets royal approval
More news
Sector news : Pharmaceuticals - NEC
03:19pDJGLAXOSMITHKLINE : FDA Approves Injectable Form Of Glaxo's Benlysta
03:05p GlaxoSmithKline's new CEO prepares to trim drug pipeline
10:00a AstraZeneca CEO reassures staff, aims to be at September cancer meet
07/20 Abbott profit forecast gets a lift from St. Jude integration
07/19DJGLAXOSMITHKLINE : to Sell Its U.K. Horlicks Brand
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on ASTRAZENECA 
2016A rally could take place
More Strategies
Latest Tweets
03:09pAstraZeneca plc's neutral rating reiterated at J P Morgan Chase & Co.  
02:12p$AZN (+0.4% pre) AstraZeneca CEO Reassures Staff, Aims to Be at September Can..
2
01:11pAstraZeneca CEO reassures staff, aims to be at September cancer meet
3
12:57pMission possible: AstraZeneca CEO Soriot rallies the troops, promising to fig..
1
12:35pAstraZeneca CEO reassures staff, aims to be at September cancer meet
8
More tweets
Qtime:107
News from SeekingAlpha
07/20 Looking For Value In The Deal Sweet Spot
07/20 AstraZeneca's Kyntheum OK'd in EU for plaque psoriasis
07/19 FDA's Flashing Green Light Boosts Novel Drug Approvals
07/19 Gedeon Richter's antipsychotic med cariprazine approved in Europe
07/18 Chaos At AstraZeneca
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 34
Average target price 67,8 $
Spread / Average Target 2,1%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA15.45%84 409
JOHNSON & JOHNSON17.36%367 897
NOVARTIS9.58%222 704
ROCHE HOLDING LTD.4.94%222 036
PFIZER3.26%199 735
MERCK AND COMPANY6.91%172 151